{"gene":"CLN3","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1995,"finding":"CLN3 encodes a novel 438 amino acid protein; a ~1 kb genomic deletion disrupting CLN3 was identified in Batten disease patients, confirming it as the disease gene.","method":"Exon amplification, genomic deletion mapping, mutation identification in patient cohorts","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple independent mutations (two deletions + splice-site mutation) in unrelated families confirmed the gene; replicated across large patient cohort","pmids":["7553855"],"is_preprint":false},{"year":1998,"finding":"CLN3 protein (battenin) is a highly glycosylated lysosomal membrane protein that is processed proteolytically in acidic compartments; confirmed by in vitro translation, immunoprecipitation, Western blotting, and Percoll density gradient fractionation.","method":"In vitro translation, Western blotting, Percoll density gradient fractionation, Triton X-114 extraction, GFP fusion expression in mammalian cells","journal":"Molecular genetics and metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal biochemical methods (fractionation, detergent extraction, immunoprecipitation) in two independent labs (PMID 9384607 and 10191115)","pmids":["9384607","10191115"],"is_preprint":false},{"year":1998,"finding":"CLN3 protein localizes to the lysosomal compartment; pulse-chase experiments showed it is synthesized as an N-glycosylated ~43 kDa polypeptide not secreted into growth medium.","method":"Pulse-chase labeling, immunoprecipitation, confocal immunofluorescence microscopy in COS-1 and HeLa cells","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (pulse-chase, confocal microscopy, immunoprecipitation), replicated across labs","pmids":["9384607"],"is_preprint":false},{"year":1999,"finding":"CLN3 protein is confirmed as a lysosomal membrane protein by immunoelectron microscopy co-localization with lysosomal markers; the common 461-677del mutant is retained in the ER and cannot reach lysosomes, while the E295K missense mutant reaches lysosomes similarly to wild-type.","method":"Immunoelectron microscopy, pulse-chase labeling, immunoprecipitation, transient expression in BHK cells and mouse primary neurons","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — immunoelectron microscopy plus pulse-chase in multiple cell types, direct comparison of mutants to wild-type","pmids":["10332042"],"is_preprint":false},{"year":1999,"finding":"CLN3 protein is targeted to lysosomal compartments via the trans-Golgi apparatus; monensin treatment causes retention in Golgi vesicular structures, indicating trafficking through the trans-Golgi network to lysosomes.","method":"GFP fusion expression, confocal laser scanning microscopy, monensin treatment, tunicamycin treatment in CHO and human neuroblastoma cells","journal":"Molecular genetics and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — GFP fusion imaging with pharmacological perturbations in two cell lines, single lab","pmids":["10191113"],"is_preprint":false},{"year":1999,"finding":"CLN3 protein suppresses apoptosis and enhances growth in NT2 neuronal precursor cells; CLN3 overexpression modulates endogenous ceramide levels, acting upstream of ceramide generation to suppress apoptosis.","method":"CLN3 overexpression in NT2 cells, apoptosis assays (vincristine, staurosporine, etoposide treatment), ceramide measurement","journal":"Molecular genetics and metabolism","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — overexpression/functional assay with ceramide measurement, single lab, two methods","pmids":["10191118"],"is_preprint":false},{"year":2000,"finding":"CLN3 protein modulates lysosomal pH homeostasis: CLN3 overexpression increases lysosomal pH in human embryonal kidney cells, while antisense inhibition acidifies lysosomal compartments. These pH changes alter intracellular processing of amyloid-beta precursor protein and cathepsin D. Mutant CLN3 (R334C) lacked these activities.","method":"CLN3 overexpression, antisense inhibition, lysosomal pH measurement, Western blotting of APP and cathepsin D processing in HEK293 cells","journal":"Molecular genetics and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function and loss-of-function (antisense) with direct pH measurement and biochemical readouts, single lab","pmids":["10924275"],"is_preprint":false},{"year":2001,"finding":"In neurons, CLN3 is not exclusively lysosomal; it localizes to synaptosomes but is excluded from synaptic vesicles, suggesting a role at the synapse distinct from its lysosomal function.","method":"In situ hybridization, immunohistochemistry, Western blot of subcellular fractions, immunofluorescence in mouse brain sections and primary retinal cultures","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — subcellular fractionation plus immunofluorescence, multiple brain regions and cell types, single lab","pmids":["11590129"],"is_preprint":false},{"year":2002,"finding":"CLN3 interacts with antisense-mediated knockdown pathway; blocking CLN3 expression in postmitotic hNT neurons causes apoptosis, demonstrating CLN3 is required for neuronal survival.","method":"Adenoviral antisense-CLN3 construct delivery to human postmitotic hNT neurons, apoptosis assays","journal":"Annals of neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct loss-of-function with defined cellular (apoptotic) phenotype, single lab","pmids":["11921051"],"is_preprint":false},{"year":2002,"finding":"The common CLN3 1.02 kb deletion results in a truncated protein missing amino acids 154-438; specific CLN3 motifs (exons 11 and 13; conserved stretches 184WSSGTGGAGLLG195, 291VYFAE295, 330VFASRSSL337) and glycosylation sites (71NQSH74 and 310NTSL313) are required for CLN3's anti-apoptotic function and normal cell growth rate.","method":"JNCL lymphoblast cell lines, transfection with mutant CLN3 cDNA constructs, cell growth rate assays, etoposide-induced apoptosis assays","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain-mapping mutagenesis with functional readouts (growth rate, apoptosis), single lab","pmids":["12189165"],"is_preprint":false},{"year":2003,"finding":"CLN3 contains five transmembrane domains, with an extracellular/intraluminal amino-terminus and a cytoplasmic carboxy-terminus, as determined by in vitro translation with glycosylation site mutagenesis.","method":"In vitro translation with canine pancreatic microsomes, Flag epitope tagging, glycosylation site mutagenesis, immunoprecipitation","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with mutagenesis establishing topology, single lab","pmids":["12706816"],"is_preprint":false},{"year":2003,"finding":"CLN3 traffics to the lysosome via the plasma membrane (cell surface); inhibition of the AP-3 adaptor protein complex subunit micro3A increased CLN3 at the cell surface, demonstrating AP-3 involvement in CLN3 lysosomal trafficking.","method":"Surface biotinylation, antibody trapping, AP-3 subunit knockdown in NCCIT cells","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — surface biotinylation and antibody trapping with AP-3 knockdown, single lab","pmids":["14644441"],"is_preprint":false},{"year":2003,"finding":"CLN3 has two lysosomal targeting motifs: a novel M(X)9G motif in the C-terminal cytosolic tail and a dileucine motif in the large cytosolic loop domain (preceded by an acidic patch). Each motif alone is sufficient for lysosomal targeting; in neurons, CLN3 also localizes to early endosomes via an endosomal association independent of these targeting motifs.","method":"Mutagenesis of targeting motifs, transfection in nonneuronal and neuronal cells, immunofluorescence confocal microscopy","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — structure-function mutagenesis of two independent sorting signals in multiple cell types, validated in neuronal and non-neuronal contexts","pmids":["14699076"],"is_preprint":false},{"year":2004,"finding":"The dileucine-based motif EEEX(8)LI in the second cytoplasmic domain of CLN3 is necessary and sufficient for lysosomal targeting; the C-terminal domain and first cytoplasmic domain are less efficient. No interaction of CLN3 cytoplasmic domains with AP-1, AP-3, or GGA3 adaptor complexes was detected using chimeric reporter proteins.","method":"Chimeric CLN3/LAMP-1/lysosomal acid phosphatase reporter constructs, cell transfection, lysosomal targeting assays, adaptor binding assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter chimera approach with multiple constructs, single lab; note: the negative result for AP adaptor binding is also mechanistically informative","pmids":["15469932"],"is_preprint":false},{"year":2004,"finding":"The dileucine motif of CLN3 binds both AP-1 and AP-3 adaptor complexes in vitro; expression in AP-1– or AP-3–deficient mouse fibroblasts showed both adaptor complexes are required for sequential lysosomal sorting of CLN3 via this motif.","method":"Biochemical binding assays (in vitro), immunofluorescence in AP-1– and AP-3–deficient mouse fibroblasts","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro binding assay combined with genetic (adaptor-deficient cell) validation of both AP-1 and AP-3, two orthogonal methods","pmids":["15598649"],"is_preprint":false},{"year":2004,"finding":"CLN3 overexpression induces aggregation of the microtubule-binding protein Hook1, potentially by mediating its dissociation from microtubules; a weak interaction between Hook1 and cytoplasmic segments of CLN3 was demonstrated by in vitro binding assay. Receptor-mediated endocytosis is defective in CLN3-deficient JNCL fibroblasts.","method":"In vitro binding assay, CLN3 overexpression, receptor-mediated endocytosis assay in JNCL fibroblasts, co-immunoprecipitation for Hook1-Rab interactions","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — in vitro binding plus cell-based endocytosis assay and co-IP, single lab","pmids":["15471887"],"is_preprint":false},{"year":2007,"finding":"CLN3 is prenylated (most likely farnesylated) at cysteine 435 via its C-terminal CAAX motif; this prenylation is required for efficient sorting in early endosomal structures and lysosomal delivery, particularly in neuronal cells. Farnesyltransferase inhibition increased CLN3 at the cell surface.","method":"Mevalonate incorporation, farnesyltransferase inhibitor treatment, C435 mutagenesis, immunofluorescence in COS7 and neuronal cells","journal":"Traffic","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — metabolic labeling (mevalonate incorporation) plus mutagenesis and pharmacological inhibition, single lab","pmids":["17286803"],"is_preprint":false},{"year":2007,"finding":"CLN3 is required for synthesis of bis(monoacylglycerol)phosphate (BMP) in lysosomes; metabolic labeling showed reduced BMP synthesis in JNCL fibroblasts and brain, restored by wild-type CLN3 complementation. CLN3 overexpression increased BMP synthesis; mutant CLN3-L170P decreased it.","method":"BMP isolation from brain detergent-resistant membranes, metabolic labeling of JNCL fibroblasts and CLN3-overexpressing cell lines, wild-type CLN3 complementation","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function, loss-of-function, and complementation with metabolic labeling, single lab","pmids":["17482562"],"is_preprint":false},{"year":2008,"finding":"CLN3 physically interacts with the plasma membrane cytoskeletal protein fodrin (alpha-spectrin) and with Na+/K+-ATPase; loss of CLN3 disrupts fodrin distribution and impairs ouabain-induced endocytosis and subcellular distribution of neuron-specific Na+/K+-ATPase in Cln3-/- mouse primary neurons, while pump activity itself is unchanged.","method":"Co-immunoprecipitation, immunostaining of fodrin in JNCL fibroblasts and Cln3-/- brain, Na+/K+-ATPase activity assay, ouabain-induced endocytosis assay in primary neurons","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — co-IP interaction plus functional Na+/K+-ATPase trafficking assay, single lab","pmids":["18621045"],"is_preprint":false},{"year":2011,"finding":"CLN3 is required for the response to oxidative stress; Drosophila lacking CLN3 function are hypersensitive to oxidative stress and fail to detoxify reactive oxygen species. CLN3 overexpression confers increased resistance to oxidative stress. Genetic interaction screen identified connections between CLN3 and core stress signalling pathways and stress granule components.","method":"Drosophila gain-of-function modifier screen, CLN3 loss-of-function, oxidative stress survival assays, ROS detoxification assays","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic modifier screen plus directed gain/loss-of-function with quantitative stress readouts in Drosophila model","pmids":["21372148"],"is_preprint":false},{"year":2012,"finding":"CLN3 interacts with motor components of both plus-end and minus-end microtubular trafficking (tubulin, dynactin, dynein, kinesin-2); CLN3 directly interacts with active GTP-bound Rab7 and with RILP (Rab7-interacting lysosomal protein that anchors dynein motor). The disease-causing CLN3E295K mutant induces perinuclear clustering of late endosomes/lysosomes.","method":"Co-immunoprecipitation, GTP-Rab7 pulldown, overexpression of CLN3 mutants in HeLa cells, immunofluorescence of late endosome markers","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — co-IP and GTP-bound Rab7 pulldown with functional localization readout, single lab","pmids":["22261744"],"is_preprint":false},{"year":2013,"finding":"CLN3 is required for normal trafficking of microdomain-associated proteins caveolin-1, syntaxin-6, and MDR1 from the trans-Golgi network (TGN) to the plasma membrane in brain endothelial cells. CLN3-null cells have reduced caveolae, impaired caveolae-mediated endocytosis, drug efflux, and cell volume regulation. CLN3 localizes to the TGN and partitions with buoyant microdomain fractions. Application of lactosylceramide rescues protein transport and caveolar endocytosis in CLN3-deficient cells.","method":"CLN3 KO brain endothelial cells, immunofluorescence, caveolae quantification by EM, drug efflux assay, volume regulation assay, fluorescent sphingolipid probes, glycosphingolipid rescue","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal functional assays (endocytosis, drug efflux, volume regulation) combined with localization and lipid rescue in CLN3 KO cells","pmids":["24227717"],"is_preprint":false},{"year":2015,"finding":"CLN3 protein is involved in intracellular Ca2+ handling; JNCL cells bearing the common CLN3 mutation show alterations in ER, mitochondrial, and lysosomal Ca2+ pools and in store-operated Ca2+ uptake, and display autophagosome accumulation reversible by Ca2+ chelation.","method":"GFP-LC3 autophagy screening assay in JNCL mouse and iPSC-derived neural progenitor cells, thapsigargin sensitivity assay, Ca2+ chelation rescue, Ca2+ pool measurements","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based screening with mechanistic follow-up in patient-derived iPSC cells, multiple Ca2+ compartment measurements, single lab","pmids":["25878248"],"is_preprint":false},{"year":2019,"finding":"CLN3-defective cells have multiple lysosomal enzyme deficiencies (28 soluble lysosomal proteins reduced); CLN3 deficiency also impairs lipid droplet degradation, alters lactosylceramide and glycosphingolipid levels, and disrupts recycling endosome/exocytic transferrin receptor trafficking.","method":"SILAC-labeled lysosome purification by magnetic separation, mass spectrometry proteomics, immunoblotting, enzyme activity assays, fluorescent lipid probes in CLN3 knock-in mouse cerebellar cell lines","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — unbiased lysosomal proteomics combined with orthogonal enzyme activity assays and functional trafficking assay, multiple independent validations","pmids":["31040178"],"is_preprint":false},{"year":2020,"finding":"CLN3 regulates Rab7A-effector interactions at late endosomes: CLN3 is required for efficient endosome-to-TGN trafficking of lysosomal sorting receptors (CI-M6PR, sortilin) because it regulates the Rab7A interaction with retromer. CLN3 is also required for the Rab7A-PLEKHM1 interaction, which mediates autophagosome-to-lysosome fusion.","method":"Co-immunoprecipitation of Rab7A effector interactions in CLN3 KO and CLN3-disease-mutant cells, live-cell imaging, sorting receptor degradation assays","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP and functional trafficking assays in both KO and disease-mutant cells, two independent pathways (retromer and PLEKHM1) validated","pmids":["32034082"],"is_preprint":false},{"year":2021,"finding":"CLN3 and CLN5 function as an endolysosomal complex: CLN5 depletion results in impaired CLN3-Rab7A interactions and downstream effector interactions; CLN3 and CLN5 together regulate endolysosome fusion, autophagy, and retromer function.","method":"Co-immunoprecipitation of CLN3-CLN5 complex, Rab7A effector interaction assays after CLN5 depletion, endolysosomal fusion assays, autophagy flux assays","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP and functional assays in CLN5-depleted and CLN3-depleted cells, single lab","pmids":["34060589"],"is_preprint":false},{"year":2021,"finding":"CLN3 is required for phagocytosis of photoreceptor outer segments (POS) by retinal pigment epithelium (RPE); a proportion of CLN3 localizes to RPE microvilli. CLN3-disease iPSC-RPE cells show decreased microvilli density and reduced POS binding and ingestion, rescued by wild-type CLN3 gene supplementation.","method":"iPSC-RPE from CLN3-disease patients, POS phagocytosis assay (binding and ingestion), immunofluorescence of RPE microvilli, wild-type CLN3 gene rescue","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — patient-derived iPSC model with quantitative phagocytosis assay and gene rescue, two orthogonal phagocytosis endpoints","pmids":["33547385"],"is_preprint":false},{"year":2022,"finding":"CLN3 is required for lysosomal egress of glycerophosphodiesters (GPDs), the end products of glycerophospholipid catabolism. Loss of CLN3 causes massive accumulation of GPDs in brain lysosomes of mice and elevated glycerophosphoinositol in CSF of Batten disease patients. CLN3 deficiency also disrupts glycerophospholipid catabolism.","method":"LysoTag mouse for tissue-specific lysosome isolation, untargeted metabolite profiling of brain lysosomes by mass spectrometry, CLN3-deficient cultured cells, CSF metabolite analysis from Batten disease patients","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — novel in vivo lysosome isolation method combined with untargeted metabolomics and cell-based validation; replicated in mouse and patient samples","pmids":["36131016"],"is_preprint":false},{"year":2023,"finding":"CLN3 functions as a vesicular trafficking hub between Golgi and lysosome compartments: CLN3 interacts with the cation-independent mannose 6-phosphate receptor (CI-M6PR) and multiple endo-lysosomal trafficking proteins. CLN3 depletion causes mis-trafficking of CI-M6PR, mis-sorting of lysosomal enzymes, and defective autophagic lysosomal reformation. CLN3 overexpression promotes formation of multiple lysosomal tubules in a CI-M6PR– and autophagy-dependent manner.","method":"Proteomics (CLN3 interactome), co-immunoprecipitation, CI-M6PR trafficking assays, lysosomal enzyme sorting assays, lysosomal tubule formation assays in CLN3 KO and overexpressing cells","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — proteomic interactome plus multiple orthogonal functional assays (M6PR trafficking, enzyme sorting, lysosomal tubule formation) in both loss- and gain-of-function contexts","pmids":["37400440"],"is_preprint":false},{"year":2010,"finding":"CLN3 physically interacts with nonmuscle myosin-IIB; loss of CLN3 in Cln3-/- cells causes myosin-IIB distribution abnormalities and a cell migration defect that mimics myosin-II inhibition by blebbistatin.","method":"Co-immunoprecipitation of CLN3 and myosin-IIB, scratch assay and transwell migration assay in Cln3-/- cells, blebbistatin inhibition comparison, immunofluorescence of myosin-IIB","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — co-IP interaction plus two independent migration assays with pharmacological mimic, single lab","pmids":["20850431"],"is_preprint":false}],"current_model":"CLN3 (battenin) is a multi-pass lysosomal/endosomal transmembrane protein with five transmembrane domains that is N-glycosylated, prenylated (farnesylated at C435), and trafficked from the ER through the trans-Golgi network to lysosomes via AP-1– and AP-3–dependent dileucine and M(X)9G sorting motifs; its primary established function is as a lysosomal egress transporter for glycerophosphodiesters (GPDs) and a vesicular trafficking hub that connects Golgi-to-lysosome transport via interactions with CI-M6PR, regulates late endosomal positioning and dynamics by modulating active Rab7A–effector (retromer, RILP, PLEKHM1) interactions in complex with CLN5, and facilitates trans-Golgi network-to-plasma membrane transport of microdomain-associated proteins including caveolin-1; loss of CLN3 globally disrupts lysosomal enzyme delivery, lipid homeostasis (including BMP synthesis and glycosphingolipid metabolism), endocytic recycling, autophagic lysosomal reformation, photoreceptor outer segment phagocytosis by RPE, and intracellular Ca2+ homeostasis."},"narrative":{"mechanistic_narrative":"CLN3 (battenin) is a multi-pass, N-glycosylated lysosomal/endosomal membrane protein whose loss causes juvenile neuronal ceroid lipofuscinosis (Batten disease), established by the identification of a recurrent ~1 kb genomic deletion in patients [PMID:7553855]. Topologically it spans the membrane five times with a luminal N-terminus and a cytosolic C-terminus [PMID:12706816], and it is delivered to lysosomes through the trans-Golgi network and the plasma membrane using a dileucine motif and a novel M(X)9G motif that engage the AP-1 and AP-3 adaptor complexes for sequential sorting [PMID:10191113, PMID:14699076, PMID:15598649], a process further dependent on C-terminal farnesylation at cysteine 435 [PMID:17286803]; the common 461-677del mutant fails this trafficking and is retained in the ER [PMID:10332042]. At the late endosome/lysosome, CLN3 acts as a vesicular trafficking hub: it binds active GTP-bound Rab7A and RILP and engages microtubule motors to govern endosome positioning [PMID:22261744], and it controls Rab7A–effector interactions with retromer and PLEKHM1 to drive endosome-to-TGN return of sorting receptors (CI-M6PR, sortilin) and autophagosome–lysosome fusion [PMID:32034082], functioning in this capacity together with CLN5 as an endolysosomal complex [PMID:34060589]. Through its interaction with CI-M6PR, CLN3 coordinates Golgi-to-lysosome enzyme delivery and autophagic lysosomal reformation [PMID:37400440]. A distinct, biochemically defined transport function is the lysosomal egress of glycerophosphodiesters, the end products of glycerophospholipid catabolism, which accumulate in CLN3-deficient brain lysosomes and patient CSF [PMID:36131016]. Consistent with these roles, CLN3 loss broadly disrupts lysosomal enzyme content and lipid homeostasis, including BMP synthesis and glycosphingolipid metabolism [PMID:17482562, PMID:31040178], TGN-to-plasma-membrane transport of microdomain proteins such as caveolin-1 [PMID:24227717], photoreceptor outer segment phagocytosis by retinal pigment epithelium [PMID:33547385], and intracellular Ca2+ handling [PMID:25878248]. Additional reported interactions with cytoskeletal and membrane proteins—fodrin/Na+/K+-ATPase, nonmuscle myosin-IIB, and Hook1—link CLN3 to endocytosis, cell migration, and membrane microdomain organization [PMID:15471887, PMID:18621045, PMID:20850431].","teleology":[{"year":1995,"claim":"Established the genetic basis of Batten disease by identifying CLN3 as a novel gene disrupted by a recurrent genomic deletion, defining the molecular target.","evidence":"Exon amplification and genomic deletion/mutation mapping in patient cohorts","pmids":["7553855"],"confidence":"High","gaps":["Gene identification gave no protein function","No subcellular localization or biochemical activity defined"]},{"year":1999,"claim":"Resolved where CLN3 acts by confirming it as a lysosomal membrane glycoprotein and showing the common deletion mutant is ER-retained while a missense mutant traffics normally, linking trafficking failure to disease.","evidence":"Immunoelectron microscopy, pulse-chase, and mutant comparison in BHK cells and primary neurons; monensin/tunicamycin trafficking studies","pmids":["10332042","9384607","10191113"],"confidence":"High","gaps":["Molecular function at the lysosome not established","Sorting machinery not yet identified"]},{"year":2003,"claim":"Defined CLN3 membrane topology (five TM domains, luminal N-terminus, cytosolic C-terminus), providing the structural framework for assigning sorting and interaction surfaces.","evidence":"In vitro translation with canine microsomes plus glycosylation-site and Flag-tag mutagenesis","pmids":["12706816"],"confidence":"Medium","gaps":["No high-resolution structure","Functional residues within TM domains not mapped"]},{"year":2004,"claim":"Identified the dileucine and M(X)9G sorting signals and showed sequential AP-1/AP-3 adaptor-dependent lysosomal delivery, explaining how CLN3 reaches its compartment.","evidence":"Targeting-motif mutagenesis, reporter chimeras, in vitro adaptor binding, and AP-1/AP-3-deficient fibroblasts","pmids":["14699076","15469932","15598649"],"confidence":"High","gaps":["Conflicting reports on direct adaptor binding via reporter chimeras","Endosomal targeting independent of these motifs not fully explained"]},{"year":2007,"claim":"Showed CLN3 is farnesylated at C435 and that this lipid modification is required for efficient endosomal/lysosomal sorting, adding a post-translational layer to trafficking control.","evidence":"Mevalonate metabolic labeling, farnesyltransferase inhibition, and C435 mutagenesis in COS7 and neuronal cells","pmids":["17286803"],"confidence":"Medium","gaps":["Mechanistic link between prenylation and sorting machinery unresolved","Single lab"]},{"year":2012,"claim":"Connected CLN3 to late-endosome dynamics by demonstrating interaction with active Rab7, RILP, and microtubule motors, with a disease mutant causing perinuclear organelle clustering.","evidence":"Co-IP, GTP-Rab7 pulldown, and mutant overexpression imaging in HeLa cells","pmids":["22261744"],"confidence":"Medium","gaps":["Direct vs indirect Rab7 binding not distinguished","Single lab"]},{"year":2019,"claim":"Demonstrated through unbiased lysosomal proteomics that CLN3 loss broadly depletes soluble lysosomal enzymes and disrupts lipid and endosomal recycling, establishing global endolysosomal dysfunction.","evidence":"SILAC lysosome purification with mass spectrometry, enzyme activity assays, and lipid probes in CLN3 knock-in mouse cells","pmids":["31040178"],"confidence":"High","gaps":["Did not pinpoint the primary biochemical defect upstream of enzyme loss"]},{"year":2020,"claim":"Provided the mechanistic basis for enzyme mis-sorting by showing CLN3 regulates Rab7A interactions with retromer and PLEKHM1, controlling sorting-receptor recycling and autophagosome-lysosome fusion.","evidence":"Reciprocal co-IP and functional trafficking assays in CLN3 KO and disease-mutant cells","pmids":["32034082"],"confidence":"High","gaps":["Structural mode of CLN3 action on Rab7A effectors unknown"]},{"year":2021,"claim":"Placed CLN3 in a CLN3-CLN5 endolysosomal complex, showing CLN5 is needed for CLN3-Rab7A function and integrating two NCL genes into a shared trafficking pathway.","evidence":"Co-IP of the complex, Rab7A effector and autophagy/fusion assays after CLN5 depletion","pmids":["34060589"],"confidence":"Medium","gaps":["Stoichiometry and direct contacts of the complex undefined","Single lab"]},{"year":2022,"claim":"Defined a concrete transport activity by identifying CLN3 as the lysosomal egress route for glycerophosphodiesters, with accumulation in mouse brain lysosomes and patient CSF.","evidence":"LysoTag in vivo lysosome isolation, untargeted metabolomics, and cell-based validation plus patient CSF analysis","pmids":["36131016"],"confidence":"High","gaps":["Direct demonstration of CLN3 as the transporter vs facilitator not fully resolved","Relationship between GPD egress and trafficking-hub roles unclear"]},{"year":2023,"claim":"Consolidated the trafficking-hub model by showing CLN3 binds CI-M6PR to coordinate Golgi-lysosome enzyme delivery and autophagic lysosomal reformation, with overexpression driving lysosomal tubulation.","evidence":"CLN3 interactome proteomics, co-IP, CI-M6PR and enzyme sorting assays, and lysosomal tubule assays in KO and overexpressing cells","pmids":["37400440"],"confidence":"High","gaps":["How the GPD transport function and the CI-M6PR hub function mechanistically relate is unresolved"]},{"year":null,"claim":"Whether CLN3's glycerophosphodiester transport activity and its Rab7A/CI-M6PR trafficking-hub functions reflect a single unified molecular mechanism or separable activities, and how either causes selective neurodegeneration, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of CLN3 in a transport or complex state","Primary defect underlying neuronal death not established","Link between metabolite accumulation and trafficking phenotypes undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[27]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[24,28]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[3,23,27]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[12,16,20]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[4,21,28]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[11]}],"pathway":[{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[24,28]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[22,24,28]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[17,23,27]},{"term_id":"R-HSA-9609507","term_label":"Protein localization","supporting_discovery_ids":[12,14]}],"complexes":["CLN3-CLN5 endolysosomal complex"],"partners":["RAB7A","RILP","PLEKHM1","CLN5","CI-M6PR (IGF2R)","MYH10","SPTAN1","HOOK1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13286","full_name":"Battenin","aliases":["Batten disease protein","Protein CLN3"],"length_aa":438,"mass_kda":47.6,"function":"Mediates microtubule-dependent, anterograde transport connecting the Golgi network, endosomes, autophagosomes, lysosomes and plasma membrane, and participates in several cellular processes such as regulation of lysosomal pH, lysosome protein degradation, receptor-mediated endocytosis, autophagy, transport of proteins and lipids from the TGN, apoptosis and synaptic transmission (PubMed:10924275, PubMed:15471887, PubMed:18317235, PubMed:18817525, PubMed:20850431, PubMed:22261744). Facilitates the proteins transport from trans-Golgi network (TGN)-to other membrane compartments such as transport of microdomain-associated proteins to the plasma membrane, IGF2R transport to the lysosome where it regulates the CTSD release leading to regulation of CTSD maturation and thereby APP intracellular processing (PubMed:10924275, PubMed:18817525). Moreover regulates CTSD activity in response to osmotic stress (PubMed:23840424, PubMed:28390177). Also binds galactosylceramide and transports it from the trans Golgi to the rafts, which may have immediate and downstream effects on cell survival by modulating ceramide synthesis (PubMed:18317235). At the plasma membrane, regulates actin-dependent events including filopodia formation, cell migration, and pinocytosis through ARF1-CDC42 pathway and also the cytoskeleton organization through interaction with MYH10 and fodrin leading to the regulation of the plasma membrane association of Na+, K+ ATPase complex (PubMed:20850431). Regulates synaptic transmission in the amygdala, hippocampus, and cerebellum through regulation of synaptic vesicles density and their proximity to active zones leading to modulation of short-term plasticity and age-dependent anxious behavior, learning and memory (By similarity). Regulates autophagic vacuoles (AVs) maturation by modulating the trafficking between endocytic and autophagolysosomal/lysosomal compartments, which involves vesicle fusion leading to regulation of degradation process (By similarity). Also participates in cellular homeostasis of compounds such as, water, ions, amino acids, proteins and lipids in several tissue namely in brain and kidney through regulation of their transport and synthesis (PubMed:17482562)","subcellular_location":"Lysosome membrane; Late endosome; Lysosome; Golgi apparatus; Golgi apparatus membrane; Golgi apparatus, Golgi stack; Golgi apparatus, trans-Golgi network; Cell membrane; Recycling endosome; Membrane raft; Membrane, caveola; Early endosome membrane; Synapse, synaptosome; Late endosome membrane; Cytoplasmic vesicle, autophagosome","url":"https://www.uniprot.org/uniprotkb/Q13286/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CLN3","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CLN3","total_profiled":1310},"omim":[{"mim_id":"621548","title":"RETINITIS PIGMENTOSA 101; RP101","url":"https://www.omim.org/entry/621548"},{"mim_id":"611726","title":"EPILEPSY, PROGRESSIVE MYOCLONIC, 3, WITH OR WITHOUT INTRACELLULAR INCLUSIONS; EPM3","url":"https://www.omim.org/entry/611726"},{"mim_id":"610951","title":"CEROID LIPOFUSCINOSIS, NEURONAL, 7; CLN7","url":"https://www.omim.org/entry/610951"},{"mim_id":"610127","title":"CEROID LIPOFUSCINOSIS, NEURONAL, 10; CLN10","url":"https://www.omim.org/entry/610127"},{"mim_id":"609055","title":"CEROID LIPOFUSCINOSIS, NEURONAL, 9; CLN9","url":"https://www.omim.org/entry/609055"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CLN3"},"hgnc":{"alias_symbol":["BTN1","JNCL","SLC29B1"],"prev_symbol":["BTS"]},"alphafold":{"accession":"Q13286","domains":[{"cath_id":"1.20.1250.20","chopping":"33-65_93-234_269-436","consensus_level":"medium","plddt":91.3801,"start":33,"end":436}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13286","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13286-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13286-F1-predicted_aligned_error_v6.png","plddt_mean":81.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CLN3","jax_strain_url":"https://www.jax.org/strain/search?query=CLN3"},"sequence":{"accession":"Q13286","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13286.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13286/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13286"}},"corpus_meta":[{"pmid":"7553855","id":"PMC_7553855","title":"Isolation of a novel gene underlying Batten disease, CLN3. The International Batten Disease Consortium.","date":"1995","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/7553855","citation_count":462,"is_preprint":false},{"pmid":"1316273","id":"PMC_1316273","title":"The Cln3-Cdc28 kinase complex of S. cerevisiae is regulated by proteolysis and phosphorylation.","date":"1992","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/1316273","citation_count":386,"is_preprint":false},{"pmid":"15210110","id":"PMC_15210110","title":"Cln3 activates G1-specific transcription via phosphorylation of the SBF bound repressor Whi5.","date":"2004","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/15210110","citation_count":318,"is_preprint":false},{"pmid":"7823941","id":"PMC_7823941","title":"p34Cdc28-mediated control of Cln3 cyclin degradation.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7823941","citation_count":271,"is_preprint":false},{"pmid":"9334317","id":"PMC_9334317","title":"Coupling of cell division to cell growth by translational control of the G1 cyclin CLN3 in yeast.","date":"1997","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9334317","citation_count":248,"is_preprint":false},{"pmid":"9311735","id":"PMC_9311735","title":"Spectrum of mutations in the Batten disease gene, CLN3.","date":"1997","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9311735","citation_count":178,"is_preprint":false},{"pmid":"9384607","id":"PMC_9384607","title":"Biosynthesis and intracellular targeting of the CLN3 protein defective in Batten disease.","date":"1998","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9384607","citation_count":164,"is_preprint":false},{"pmid":"12374761","id":"PMC_12374761","title":"Cln3(Deltaex7/8) knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth.","date":"2002","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12374761","citation_count":162,"is_preprint":false},{"pmid":"15471887","id":"PMC_15471887","title":"Interconnections of CLN3, Hook1 and Rab proteins link Batten disease to defects in the endocytic pathway.","date":"2004","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15471887","citation_count":122,"is_preprint":false},{"pmid":"36131016","id":"PMC_36131016","title":"CLN3 is required for the clearance of glycerophosphodiesters from lysosomes.","date":"2022","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/36131016","citation_count":117,"is_preprint":false},{"pmid":"15802219","id":"PMC_15802219","title":"Production, purification, and characterization of lipase from thermophilic and alkaliphilic Bacillus coagulans BTS-3.","date":"2005","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/15802219","citation_count":108,"is_preprint":false},{"pmid":"15657902","id":"PMC_15657902","title":"CLN3, the protein associated with batten disease: structure, function and localization.","date":"2005","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/15657902","citation_count":100,"is_preprint":false},{"pmid":"10332042","id":"PMC_10332042","title":"Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL).","date":"1999","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10332042","citation_count":99,"is_preprint":false},{"pmid":"11590129","id":"PMC_11590129","title":"CLN3 protein is targeted to neuronal synapses but excluded from synaptic vesicles: new clues to Batten disease.","date":"2001","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11590129","citation_count":99,"is_preprint":false},{"pmid":"14699076","id":"PMC_14699076","title":"Two motifs target Batten disease protein CLN3 to lysosomes in transfected nonneuronal and neuronal cells.","date":"2003","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/14699076","citation_count":97,"is_preprint":false},{"pmid":"9687505","id":"PMC_9687505","title":"Regulation of the Cln3-Cdc28 kinase by cAMP in Saccharomyces cerevisiae.","date":"1998","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9687505","citation_count":96,"is_preprint":false},{"pmid":"10924275","id":"PMC_10924275","title":"CLN3 protein regulates lysosomal pH and alters intracellular processing of Alzheimer's amyloid-beta protein precursor and cathepsin D in human cells.","date":"2000","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10924275","citation_count":96,"is_preprint":false},{"pmid":"17560371","id":"PMC_17560371","title":"Cyclin Cln3 is retained at the ER and released by the J chaperone Ydj1 in late G1 to trigger cell cycle entry.","date":"2007","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/17560371","citation_count":90,"is_preprint":false},{"pmid":"10191118","id":"PMC_10191118","title":"CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide.","date":"1999","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10191118","citation_count":87,"is_preprint":false},{"pmid":"19823669","id":"PMC_19823669","title":"Recruitment of Cln3 cyclin to promoters controls cell cycle entry via histone deacetylase and other targets.","date":"2009","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/19823669","citation_count":85,"is_preprint":false},{"pmid":"15626411","id":"PMC_15626411","title":"New assays for detection and localization of endogenous lipid peroxidation products in living boar sperm after BTS dilution or after freeze-thawing.","date":"2005","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/15626411","citation_count":85,"is_preprint":false},{"pmid":"23408996","id":"PMC_23408996","title":"Alterations in ROS activity and lysosomal pH account for distinct patterns of macroautophagy in LINCL and JNCL fibroblasts.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23408996","citation_count":83,"is_preprint":false},{"pmid":"10749980","id":"PMC_10749980","title":"Batten disease: evaluation of CLN3 mutations on protein localization and function.","date":"2000","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10749980","citation_count":79,"is_preprint":false},{"pmid":"12024050","id":"PMC_12024050","title":"The G(1) cyclin Cln3 promotes cell cycle entry via the transcription factor Swi6.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12024050","citation_count":78,"is_preprint":false},{"pmid":"8497251","id":"PMC_8497251","title":"The yeast Cln3 protein is an unstable activator of Cdc28.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8497251","citation_count":75,"is_preprint":false},{"pmid":"22545070","id":"PMC_22545070","title":"The juvenile Batten disease protein, CLN3, and its role in regulating anterograde and retrograde post-Golgi trafficking.","date":"2012","source":"Clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/22545070","citation_count":69,"is_preprint":false},{"pmid":"25878248","id":"PMC_25878248","title":"Unbiased Cell-based Screening in a Neuronal Cell Model of Batten Disease Highlights an Interaction between Ca2+ Homeostasis, Autophagy, and CLN3 Protein Function.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25878248","citation_count":69,"is_preprint":false},{"pmid":"31568712","id":"PMC_31568712","title":"The CLN3 gene and protein: What we know.","date":"2019","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31568712","citation_count":66,"is_preprint":false},{"pmid":"22261744","id":"PMC_22261744","title":"Neuronal ceroid lipofuscinosis protein CLN3 interacts with motor proteins and modifies location of late endosomal compartments.","date":"2012","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/22261744","citation_count":66,"is_preprint":false},{"pmid":"11251821","id":"PMC_11251821","title":"Osmotic stress causes a G1 cell cycle delay and downregulation of Cln3/Cdc28 activity in Saccharomyces cerevisiae.","date":"2001","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/11251821","citation_count":64,"is_preprint":false},{"pmid":"16941499","id":"PMC_16941499","title":"Batten disease (JNCL) is linked to disturbances in mitochondrial, cytoskeletal, and synaptic compartments.","date":"2006","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/16941499","citation_count":62,"is_preprint":false},{"pmid":"27629717","id":"PMC_27629717","title":"Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3).","date":"2016","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27629717","citation_count":59,"is_preprint":false},{"pmid":"15643064","id":"PMC_15643064","title":"The G1 cyclin Cln3 regulates morphogenesis in Candida albicans.","date":"2005","source":"Eukaryotic cell","url":"https://pubmed.ncbi.nlm.nih.gov/15643064","citation_count":59,"is_preprint":false},{"pmid":"12189165","id":"PMC_12189165","title":"Motifs within the CLN3 protein: modulation of cell growth rates and apoptosis.","date":"2002","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12189165","citation_count":58,"is_preprint":false},{"pmid":"21359198","id":"PMC_21359198","title":"Distinct early molecular responses to mutations causing vLINCL and JNCL presage ATP synthase subunit C accumulation in cerebellar cells.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21359198","citation_count":56,"is_preprint":false},{"pmid":"22701626","id":"PMC_22701626","title":"Large-scale phenotyping of an accurate genetic mouse model of JNCL identifies novel early pathology outside the central nervous system.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22701626","citation_count":54,"is_preprint":false},{"pmid":"11921051","id":"PMC_11921051","title":"Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons.","date":"2002","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11921051","citation_count":54,"is_preprint":false},{"pmid":"11839825","id":"PMC_11839825","title":"AZF1 is a glucose-dependent positive regulator of CLN3 transcription in Saccharomyces cerevisiae.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11839825","citation_count":52,"is_preprint":false},{"pmid":"24227717","id":"PMC_24227717","title":"CLN3 loss disturbs membrane microdomain properties and protein transport in brain endothelial cells.","date":"2013","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24227717","citation_count":51,"is_preprint":false},{"pmid":"15469932","id":"PMC_15469932","title":"A dileucine motif and a cluster of acidic amino acids in the second cytoplasmic domain of the batten disease-related CLN3 protein are required for efficient lysosomal targeting.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15469932","citation_count":51,"is_preprint":false},{"pmid":"15598649","id":"PMC_15598649","title":"AP-1 and AP-3 facilitate lysosomal targeting of Batten disease protein CLN3 via its dileucine motif.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15598649","citation_count":50,"is_preprint":false},{"pmid":"7887419","id":"PMC_7887419","title":"Batten disease gene, CLN3: linkage disequilibrium mapping in the Finnish population, and analysis of European haplotypes.","date":"1995","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7887419","citation_count":50,"is_preprint":false},{"pmid":"10477428","id":"PMC_10477428","title":"Molecular basis of the neuronal ceroid lipofuscinoses: mutations in CLN1, CLN2, CLN3, and CLN5.","date":"1999","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/10477428","citation_count":50,"is_preprint":false},{"pmid":"24736558","id":"PMC_24736558","title":"Evidence for aberrant astrocyte hemichannel activity in Juvenile Neuronal Ceroid Lipofuscinosis (JNCL).","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24736558","citation_count":49,"is_preprint":false},{"pmid":"10191116","id":"PMC_10191116","title":"Tissue expression and subcellular localization of CLN3, the Batten disease protein.","date":"1999","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10191116","citation_count":49,"is_preprint":false},{"pmid":"1746562","id":"PMC_1746562","title":"Regional mapping of the Batten disease locus (CLN3) to human chromosome 16p12.","date":"1991","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1746562","citation_count":49,"is_preprint":false},{"pmid":"31040178","id":"PMC_31040178","title":"Lysosomal proteome analysis reveals that CLN3-defective cells have multiple enzyme deficiencies associated with changes in intracellular trafficking.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31040178","citation_count":49,"is_preprint":false},{"pmid":"21372148","id":"PMC_21372148","title":"The Batten disease gene CLN3 is required for the response to oxidative stress.","date":"2011","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21372148","citation_count":47,"is_preprint":false},{"pmid":"15251239","id":"PMC_15251239","title":"Boar sperm storage capacity of BTS and Androhep Plus: viability, motility, capacitation, and tyrosine phosphorylation.","date":"2004","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/15251239","citation_count":47,"is_preprint":false},{"pmid":"31926949","id":"PMC_31926949","title":"Juvenile Batten Disease (CLN3): Detailed Ocular Phenotype, Novel Observations, Delayed Diagnosis, Masquerades, and Prospects for Therapy.","date":"2019","source":"Ophthalmology. Retina","url":"https://pubmed.ncbi.nlm.nih.gov/31926949","citation_count":47,"is_preprint":false},{"pmid":"11830536","id":"PMC_11830536","title":"The CLN3 gene is a novel molecular target for cancer drug discovery.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11830536","citation_count":45,"is_preprint":false},{"pmid":"9418890","id":"PMC_9418890","title":"Cln3-associated kinase activity in Saccharomyces cerevisiae is regulated by the mating factor pathway.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9418890","citation_count":45,"is_preprint":false},{"pmid":"32719489","id":"PMC_32719489","title":"Therapeutic efficacy of antisense oligonucleotides in mouse models of CLN3 Batten disease.","date":"2020","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32719489","citation_count":45,"is_preprint":false},{"pmid":"15520229","id":"PMC_15520229","title":"A cell sizer network involving Cln3 and Far1 controls entrance into S phase in the mitotic cycle of budding yeast.","date":"2004","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15520229","citation_count":45,"is_preprint":false},{"pmid":"11390643","id":"PMC_11390643","title":"Early cell cycle box-mediated transcription of CLN3 and SWI4 contributes to the proper timing of the G(1)-to-S transition in budding yeast.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11390643","citation_count":45,"is_preprint":false},{"pmid":"21863212","id":"PMC_21863212","title":"Analysis of potential biomarkers and modifier genes affecting the clinical course of CLN3 disease.","date":"2011","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/21863212","citation_count":45,"is_preprint":false},{"pmid":"31676164","id":"PMC_31676164","title":"Knockdown of BTS may provide a new strategy to improve cadmium-phytoremediation efficiency by improving iron status in plants.","date":"2019","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/31676164","citation_count":44,"is_preprint":false},{"pmid":"9119403","id":"PMC_9119403","title":"Genomic structure and complete nucleotide sequence of the Batten disease gene, CLN3.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9119403","citation_count":42,"is_preprint":false},{"pmid":"18621045","id":"PMC_18621045","title":"Novel interactions of CLN3 protein link Batten disease to dysregulation of fodrin-Na+, K+ ATPase complex.","date":"2008","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18621045","citation_count":42,"is_preprint":false},{"pmid":"37400440","id":"PMC_37400440","title":"Loss of the batten disease protein CLN3 leads to mis-trafficking of M6PR and defective autophagic-lysosomal reformation.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37400440","citation_count":41,"is_preprint":false},{"pmid":"12706816","id":"PMC_12706816","title":"Membrane topology of CLN3, the protein underlying Batten disease.","date":"2003","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/12706816","citation_count":41,"is_preprint":false},{"pmid":"9440509","id":"PMC_9440509","title":"Growth-independent regulation of CLN3 mRNA levels by nutrients in Saccharomyces cerevisiae.","date":"1998","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/9440509","citation_count":41,"is_preprint":false},{"pmid":"34411438","id":"PMC_34411438","title":"Repurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype.","date":"2021","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34411438","citation_count":40,"is_preprint":false},{"pmid":"12081645","id":"PMC_12081645","title":"The CLN3/SWI6/CLN2 pathway and SNF1 act sequentially to regulate meiotic initiation in Saccharomyces cerevisiae.","date":"2002","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/12081645","citation_count":40,"is_preprint":false},{"pmid":"17482562","id":"PMC_17482562","title":"A novel role of the Batten disease gene CLN3: association with BMP synthesis.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17482562","citation_count":40,"is_preprint":false},{"pmid":"19028667","id":"PMC_19028667","title":"Interactions between the juvenile Batten disease gene, CLN3, and the Notch and JNK signalling pathways.","date":"2008","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19028667","citation_count":39,"is_preprint":false},{"pmid":"20850431","id":"PMC_20850431","title":"A novel interaction of CLN3 with nonmuscle myosin-IIB and defects in cell motility of Cln3(-/-) cells.","date":"2010","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/20850431","citation_count":39,"is_preprint":false},{"pmid":"10191113","id":"PMC_10191113","title":"Analysis of intracellular distribution and trafficking of the CLN3 protein in fusion with the green fluorescent protein in vitro.","date":"1999","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10191113","citation_count":39,"is_preprint":false},{"pmid":"10658181","id":"PMC_10658181","title":"Localization and processing of CLN3, the protein associated to Batten disease: where is it and what does it do?","date":"2000","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/10658181","citation_count":37,"is_preprint":false},{"pmid":"28600888","id":"PMC_28600888","title":"Homeostatic control of START through negative feedback between Cln3-Cdk1 and Rim15/Greatwall kinase in budding yeast.","date":"2017","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/28600888","citation_count":36,"is_preprint":false},{"pmid":"24386402","id":"PMC_24386402","title":"Effects of the yeast RNA-binding protein Whi3 on the half-life and abundance of CLN3 mRNA and other targets.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24386402","citation_count":36,"is_preprint":false},{"pmid":"26748992","id":"PMC_26748992","title":"Vision loss in juvenile neuronal ceroid lipofuscinosis (CLN3 disease).","date":"2016","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26748992","citation_count":35,"is_preprint":false},{"pmid":"32034082","id":"PMC_32034082","title":"CLN3 regulates endosomal function by modulating Rab7A-effector interactions.","date":"2020","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/32034082","citation_count":35,"is_preprint":false},{"pmid":"33547385","id":"PMC_33547385","title":"A human model of Batten disease shows role of CLN3 in phagocytosis at the photoreceptor-RPE interface.","date":"2021","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/33547385","citation_count":34,"is_preprint":false},{"pmid":"27804148","id":"PMC_27804148","title":"Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease (CLN3).","date":"2016","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27804148","citation_count":33,"is_preprint":false},{"pmid":"10191115","id":"PMC_10191115","title":"Expression studies of CLN3 protein (battenin) in fusion with the green fluorescent protein in mammalian cells in vitro.","date":"1999","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10191115","citation_count":33,"is_preprint":false},{"pmid":"17286803","id":"PMC_17286803","title":"C-terminal prenylation of the CLN3 membrane glycoprotein is required for efficient endosomal sorting to lysosomes.","date":"2007","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/17286803","citation_count":33,"is_preprint":false},{"pmid":"9721289","id":"PMC_9721289","title":"Transcriptional regulation of CLN3 expression by glucose in Saccharomyces cerevisiae.","date":"1998","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/9721289","citation_count":33,"is_preprint":false},{"pmid":"32592935","id":"PMC_32592935","title":"Loss of CLN3, the gene mutated in juvenile neuronal ceroid lipofuscinosis, leads to metabolic impairment and autophagy induction in retinal pigment epithelium.","date":"2020","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/32592935","citation_count":32,"is_preprint":false},{"pmid":"18678598","id":"PMC_18678598","title":"Transcript and in silico analysis of CLN3 in juvenile neuronal ceroid lipofuscinosis and associated mouse models.","date":"2008","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18678598","citation_count":31,"is_preprint":false},{"pmid":"17868323","id":"PMC_17868323","title":"Increased expression of lysosomal acid phosphatase in CLN3-defective cells and mouse brain tissue.","date":"2007","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17868323","citation_count":31,"is_preprint":false},{"pmid":"28365442","id":"PMC_28365442","title":"Loss of Cln3 impacts protein secretion in the social amoeba Dictyostelium.","date":"2017","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/28365442","citation_count":31,"is_preprint":false},{"pmid":"24827497","id":"PMC_24827497","title":"Novel CLN3 mutation causing autophagic vacuolar myopathy.","date":"2014","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24827497","citation_count":29,"is_preprint":false},{"pmid":"16987179","id":"PMC_16987179","title":"The F-box protein Grr1 regulates the stability of Ccn1, Cln3 and Hof1 and cell morphogenesis in Candida albicans.","date":"2006","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/16987179","citation_count":29,"is_preprint":false},{"pmid":"27400765","id":"PMC_27400765","title":"Using Patient-Specific Induced Pluripotent Stem Cells and Wild-Type Mice to Develop a Gene Augmentation-Based Strategy to Treat CLN3-Associated Retinal Degeneration.","date":"2016","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27400765","citation_count":29,"is_preprint":false},{"pmid":"30251676","id":"PMC_30251676","title":"Cln3 function is linked to osmoregulation in a Dictyostelium model of Batten disease.","date":"2018","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/30251676","citation_count":28,"is_preprint":false},{"pmid":"34274435","id":"PMC_34274435","title":"CLN3, at the crossroads of endocytic trafficking.","date":"2021","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/34274435","citation_count":27,"is_preprint":false},{"pmid":"23840424","id":"PMC_23840424","title":"Osmotic stress changes the expression and subcellular localization of the Batten disease protein CLN3.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23840424","citation_count":27,"is_preprint":false},{"pmid":"8812504","id":"PMC_8812504","title":"Isolation and chromosomal mapping of a mouse homolog of the Batten disease gene CLN3.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8812504","citation_count":27,"is_preprint":false},{"pmid":"34060589","id":"PMC_34060589","title":"CLN5 and CLN3 function as a complex to regulate endolysosome function.","date":"2021","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/34060589","citation_count":26,"is_preprint":false},{"pmid":"27327661","id":"PMC_27327661","title":"Neurodegeneration and Epilepsy in a Zebrafish Model of CLN3 Disease (Batten Disease).","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27327661","citation_count":26,"is_preprint":false},{"pmid":"8971698","id":"PMC_8971698","title":"Mitochondrial abnormalities in CLN2 and CLN3 forms of Batten disease.","date":"1996","source":"Molecular and chemical neuropathology","url":"https://pubmed.ncbi.nlm.nih.gov/8971698","citation_count":25,"is_preprint":false},{"pmid":"14644441","id":"PMC_14644441","title":"Intracellular trafficking of CLN3, the protein underlying the childhood neurodegenerative disease, Batten disease.","date":"2003","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/14644441","citation_count":25,"is_preprint":false},{"pmid":"11001812","id":"PMC_11001812","title":"Neural and extraneural expression of the neuronal ceroid lipofuscinoses genes CLN1, CLN2, and CLN3: functional implications for CLN3.","date":"2000","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11001812","citation_count":24,"is_preprint":false},{"pmid":"23628560","id":"PMC_23628560","title":"Methodology of clinical research in rare diseases: development of a research program in juvenile neuronal ceroid lipofuscinosis (JNCL) via creation of a patient registry and collaboration with patient advocates.","date":"2013","source":"Contemporary clinical trials","url":"https://pubmed.ncbi.nlm.nih.gov/23628560","citation_count":24,"is_preprint":false},{"pmid":"29964296","id":"PMC_29964296","title":"Astrocytes in juvenile neuronal ceroid lipofuscinosis (CLN3) display metabolic and calcium signaling abnormalities.","date":"2018","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29964296","citation_count":24,"is_preprint":false},{"pmid":"9492089","id":"PMC_9492089","title":"Studies of atypical JNCL suggest overlapping with other NCL forms.","date":"1998","source":"Pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/9492089","citation_count":23,"is_preprint":false},{"pmid":"33073192","id":"PMC_33073192","title":"An iPSC-Derived Neuron Model of CLN3 Disease Facilitates Small Molecule Phenotypic Screening.","date":"2020","source":"ACS pharmacology & translational science","url":"https://pubmed.ncbi.nlm.nih.gov/33073192","citation_count":22,"is_preprint":false},{"pmid":"30446867","id":"PMC_30446867","title":"Clinical and molecular characterization of non-syndromic retinal dystrophy due to c.175G>A mutation in ceroid lipofuscinosis neuronal 3 (CLN3).","date":"2018","source":"Documenta ophthalmologica. Advances in ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/30446867","citation_count":22,"is_preprint":false},{"pmid":"30771446","id":"PMC_30771446","title":"Comparative transcriptomics reveals mechanisms underlying cln3-deficiency phenotypes in Dictyostelium.","date":"2019","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/30771446","citation_count":21,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47963,"output_tokens":7453,"usd":0.127842,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16741,"output_tokens":4073,"usd":0.092765,"stage2_stop_reason":"end_turn"},"total_usd":0.220607,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"CLN3 encodes a novel 438 amino acid protein; a ~1 kb genomic deletion disrupting CLN3 was identified in Batten disease patients, confirming it as the disease gene.\",\n      \"method\": \"Exon amplification, genomic deletion mapping, mutation identification in patient cohorts\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple independent mutations (two deletions + splice-site mutation) in unrelated families confirmed the gene; replicated across large patient cohort\",\n      \"pmids\": [\"7553855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CLN3 protein (battenin) is a highly glycosylated lysosomal membrane protein that is processed proteolytically in acidic compartments; confirmed by in vitro translation, immunoprecipitation, Western blotting, and Percoll density gradient fractionation.\",\n      \"method\": \"In vitro translation, Western blotting, Percoll density gradient fractionation, Triton X-114 extraction, GFP fusion expression in mammalian cells\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal biochemical methods (fractionation, detergent extraction, immunoprecipitation) in two independent labs (PMID 9384607 and 10191115)\",\n      \"pmids\": [\"9384607\", \"10191115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CLN3 protein localizes to the lysosomal compartment; pulse-chase experiments showed it is synthesized as an N-glycosylated ~43 kDa polypeptide not secreted into growth medium.\",\n      \"method\": \"Pulse-chase labeling, immunoprecipitation, confocal immunofluorescence microscopy in COS-1 and HeLa cells\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (pulse-chase, confocal microscopy, immunoprecipitation), replicated across labs\",\n      \"pmids\": [\"9384607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CLN3 protein is confirmed as a lysosomal membrane protein by immunoelectron microscopy co-localization with lysosomal markers; the common 461-677del mutant is retained in the ER and cannot reach lysosomes, while the E295K missense mutant reaches lysosomes similarly to wild-type.\",\n      \"method\": \"Immunoelectron microscopy, pulse-chase labeling, immunoprecipitation, transient expression in BHK cells and mouse primary neurons\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — immunoelectron microscopy plus pulse-chase in multiple cell types, direct comparison of mutants to wild-type\",\n      \"pmids\": [\"10332042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CLN3 protein is targeted to lysosomal compartments via the trans-Golgi apparatus; monensin treatment causes retention in Golgi vesicular structures, indicating trafficking through the trans-Golgi network to lysosomes.\",\n      \"method\": \"GFP fusion expression, confocal laser scanning microscopy, monensin treatment, tunicamycin treatment in CHO and human neuroblastoma cells\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — GFP fusion imaging with pharmacological perturbations in two cell lines, single lab\",\n      \"pmids\": [\"10191113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CLN3 protein suppresses apoptosis and enhances growth in NT2 neuronal precursor cells; CLN3 overexpression modulates endogenous ceramide levels, acting upstream of ceramide generation to suppress apoptosis.\",\n      \"method\": \"CLN3 overexpression in NT2 cells, apoptosis assays (vincristine, staurosporine, etoposide treatment), ceramide measurement\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — overexpression/functional assay with ceramide measurement, single lab, two methods\",\n      \"pmids\": [\"10191118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CLN3 protein modulates lysosomal pH homeostasis: CLN3 overexpression increases lysosomal pH in human embryonal kidney cells, while antisense inhibition acidifies lysosomal compartments. These pH changes alter intracellular processing of amyloid-beta precursor protein and cathepsin D. Mutant CLN3 (R334C) lacked these activities.\",\n      \"method\": \"CLN3 overexpression, antisense inhibition, lysosomal pH measurement, Western blotting of APP and cathepsin D processing in HEK293 cells\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function and loss-of-function (antisense) with direct pH measurement and biochemical readouts, single lab\",\n      \"pmids\": [\"10924275\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"In neurons, CLN3 is not exclusively lysosomal; it localizes to synaptosomes but is excluded from synaptic vesicles, suggesting a role at the synapse distinct from its lysosomal function.\",\n      \"method\": \"In situ hybridization, immunohistochemistry, Western blot of subcellular fractions, immunofluorescence in mouse brain sections and primary retinal cultures\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — subcellular fractionation plus immunofluorescence, multiple brain regions and cell types, single lab\",\n      \"pmids\": [\"11590129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CLN3 interacts with antisense-mediated knockdown pathway; blocking CLN3 expression in postmitotic hNT neurons causes apoptosis, demonstrating CLN3 is required for neuronal survival.\",\n      \"method\": \"Adenoviral antisense-CLN3 construct delivery to human postmitotic hNT neurons, apoptosis assays\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct loss-of-function with defined cellular (apoptotic) phenotype, single lab\",\n      \"pmids\": [\"11921051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The common CLN3 1.02 kb deletion results in a truncated protein missing amino acids 154-438; specific CLN3 motifs (exons 11 and 13; conserved stretches 184WSSGTGGAGLLG195, 291VYFAE295, 330VFASRSSL337) and glycosylation sites (71NQSH74 and 310NTSL313) are required for CLN3's anti-apoptotic function and normal cell growth rate.\",\n      \"method\": \"JNCL lymphoblast cell lines, transfection with mutant CLN3 cDNA constructs, cell growth rate assays, etoposide-induced apoptosis assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-mapping mutagenesis with functional readouts (growth rate, apoptosis), single lab\",\n      \"pmids\": [\"12189165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CLN3 contains five transmembrane domains, with an extracellular/intraluminal amino-terminus and a cytoplasmic carboxy-terminus, as determined by in vitro translation with glycosylation site mutagenesis.\",\n      \"method\": \"In vitro translation with canine pancreatic microsomes, Flag epitope tagging, glycosylation site mutagenesis, immunoprecipitation\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with mutagenesis establishing topology, single lab\",\n      \"pmids\": [\"12706816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CLN3 traffics to the lysosome via the plasma membrane (cell surface); inhibition of the AP-3 adaptor protein complex subunit micro3A increased CLN3 at the cell surface, demonstrating AP-3 involvement in CLN3 lysosomal trafficking.\",\n      \"method\": \"Surface biotinylation, antibody trapping, AP-3 subunit knockdown in NCCIT cells\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — surface biotinylation and antibody trapping with AP-3 knockdown, single lab\",\n      \"pmids\": [\"14644441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CLN3 has two lysosomal targeting motifs: a novel M(X)9G motif in the C-terminal cytosolic tail and a dileucine motif in the large cytosolic loop domain (preceded by an acidic patch). Each motif alone is sufficient for lysosomal targeting; in neurons, CLN3 also localizes to early endosomes via an endosomal association independent of these targeting motifs.\",\n      \"method\": \"Mutagenesis of targeting motifs, transfection in nonneuronal and neuronal cells, immunofluorescence confocal microscopy\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — structure-function mutagenesis of two independent sorting signals in multiple cell types, validated in neuronal and non-neuronal contexts\",\n      \"pmids\": [\"14699076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The dileucine-based motif EEEX(8)LI in the second cytoplasmic domain of CLN3 is necessary and sufficient for lysosomal targeting; the C-terminal domain and first cytoplasmic domain are less efficient. No interaction of CLN3 cytoplasmic domains with AP-1, AP-3, or GGA3 adaptor complexes was detected using chimeric reporter proteins.\",\n      \"method\": \"Chimeric CLN3/LAMP-1/lysosomal acid phosphatase reporter constructs, cell transfection, lysosomal targeting assays, adaptor binding assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter chimera approach with multiple constructs, single lab; note: the negative result for AP adaptor binding is also mechanistically informative\",\n      \"pmids\": [\"15469932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The dileucine motif of CLN3 binds both AP-1 and AP-3 adaptor complexes in vitro; expression in AP-1– or AP-3–deficient mouse fibroblasts showed both adaptor complexes are required for sequential lysosomal sorting of CLN3 via this motif.\",\n      \"method\": \"Biochemical binding assays (in vitro), immunofluorescence in AP-1– and AP-3–deficient mouse fibroblasts\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro binding assay combined with genetic (adaptor-deficient cell) validation of both AP-1 and AP-3, two orthogonal methods\",\n      \"pmids\": [\"15598649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CLN3 overexpression induces aggregation of the microtubule-binding protein Hook1, potentially by mediating its dissociation from microtubules; a weak interaction between Hook1 and cytoplasmic segments of CLN3 was demonstrated by in vitro binding assay. Receptor-mediated endocytosis is defective in CLN3-deficient JNCL fibroblasts.\",\n      \"method\": \"In vitro binding assay, CLN3 overexpression, receptor-mediated endocytosis assay in JNCL fibroblasts, co-immunoprecipitation for Hook1-Rab interactions\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — in vitro binding plus cell-based endocytosis assay and co-IP, single lab\",\n      \"pmids\": [\"15471887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CLN3 is prenylated (most likely farnesylated) at cysteine 435 via its C-terminal CAAX motif; this prenylation is required for efficient sorting in early endosomal structures and lysosomal delivery, particularly in neuronal cells. Farnesyltransferase inhibition increased CLN3 at the cell surface.\",\n      \"method\": \"Mevalonate incorporation, farnesyltransferase inhibitor treatment, C435 mutagenesis, immunofluorescence in COS7 and neuronal cells\",\n      \"journal\": \"Traffic\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — metabolic labeling (mevalonate incorporation) plus mutagenesis and pharmacological inhibition, single lab\",\n      \"pmids\": [\"17286803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CLN3 is required for synthesis of bis(monoacylglycerol)phosphate (BMP) in lysosomes; metabolic labeling showed reduced BMP synthesis in JNCL fibroblasts and brain, restored by wild-type CLN3 complementation. CLN3 overexpression increased BMP synthesis; mutant CLN3-L170P decreased it.\",\n      \"method\": \"BMP isolation from brain detergent-resistant membranes, metabolic labeling of JNCL fibroblasts and CLN3-overexpressing cell lines, wild-type CLN3 complementation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function, loss-of-function, and complementation with metabolic labeling, single lab\",\n      \"pmids\": [\"17482562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CLN3 physically interacts with the plasma membrane cytoskeletal protein fodrin (alpha-spectrin) and with Na+/K+-ATPase; loss of CLN3 disrupts fodrin distribution and impairs ouabain-induced endocytosis and subcellular distribution of neuron-specific Na+/K+-ATPase in Cln3-/- mouse primary neurons, while pump activity itself is unchanged.\",\n      \"method\": \"Co-immunoprecipitation, immunostaining of fodrin in JNCL fibroblasts and Cln3-/- brain, Na+/K+-ATPase activity assay, ouabain-induced endocytosis assay in primary neurons\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — co-IP interaction plus functional Na+/K+-ATPase trafficking assay, single lab\",\n      \"pmids\": [\"18621045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CLN3 is required for the response to oxidative stress; Drosophila lacking CLN3 function are hypersensitive to oxidative stress and fail to detoxify reactive oxygen species. CLN3 overexpression confers increased resistance to oxidative stress. Genetic interaction screen identified connections between CLN3 and core stress signalling pathways and stress granule components.\",\n      \"method\": \"Drosophila gain-of-function modifier screen, CLN3 loss-of-function, oxidative stress survival assays, ROS detoxification assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic modifier screen plus directed gain/loss-of-function with quantitative stress readouts in Drosophila model\",\n      \"pmids\": [\"21372148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CLN3 interacts with motor components of both plus-end and minus-end microtubular trafficking (tubulin, dynactin, dynein, kinesin-2); CLN3 directly interacts with active GTP-bound Rab7 and with RILP (Rab7-interacting lysosomal protein that anchors dynein motor). The disease-causing CLN3E295K mutant induces perinuclear clustering of late endosomes/lysosomes.\",\n      \"method\": \"Co-immunoprecipitation, GTP-Rab7 pulldown, overexpression of CLN3 mutants in HeLa cells, immunofluorescence of late endosome markers\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — co-IP and GTP-bound Rab7 pulldown with functional localization readout, single lab\",\n      \"pmids\": [\"22261744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CLN3 is required for normal trafficking of microdomain-associated proteins caveolin-1, syntaxin-6, and MDR1 from the trans-Golgi network (TGN) to the plasma membrane in brain endothelial cells. CLN3-null cells have reduced caveolae, impaired caveolae-mediated endocytosis, drug efflux, and cell volume regulation. CLN3 localizes to the TGN and partitions with buoyant microdomain fractions. Application of lactosylceramide rescues protein transport and caveolar endocytosis in CLN3-deficient cells.\",\n      \"method\": \"CLN3 KO brain endothelial cells, immunofluorescence, caveolae quantification by EM, drug efflux assay, volume regulation assay, fluorescent sphingolipid probes, glycosphingolipid rescue\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal functional assays (endocytosis, drug efflux, volume regulation) combined with localization and lipid rescue in CLN3 KO cells\",\n      \"pmids\": [\"24227717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CLN3 protein is involved in intracellular Ca2+ handling; JNCL cells bearing the common CLN3 mutation show alterations in ER, mitochondrial, and lysosomal Ca2+ pools and in store-operated Ca2+ uptake, and display autophagosome accumulation reversible by Ca2+ chelation.\",\n      \"method\": \"GFP-LC3 autophagy screening assay in JNCL mouse and iPSC-derived neural progenitor cells, thapsigargin sensitivity assay, Ca2+ chelation rescue, Ca2+ pool measurements\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based screening with mechanistic follow-up in patient-derived iPSC cells, multiple Ca2+ compartment measurements, single lab\",\n      \"pmids\": [\"25878248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CLN3-defective cells have multiple lysosomal enzyme deficiencies (28 soluble lysosomal proteins reduced); CLN3 deficiency also impairs lipid droplet degradation, alters lactosylceramide and glycosphingolipid levels, and disrupts recycling endosome/exocytic transferrin receptor trafficking.\",\n      \"method\": \"SILAC-labeled lysosome purification by magnetic separation, mass spectrometry proteomics, immunoblotting, enzyme activity assays, fluorescent lipid probes in CLN3 knock-in mouse cerebellar cell lines\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — unbiased lysosomal proteomics combined with orthogonal enzyme activity assays and functional trafficking assay, multiple independent validations\",\n      \"pmids\": [\"31040178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CLN3 regulates Rab7A-effector interactions at late endosomes: CLN3 is required for efficient endosome-to-TGN trafficking of lysosomal sorting receptors (CI-M6PR, sortilin) because it regulates the Rab7A interaction with retromer. CLN3 is also required for the Rab7A-PLEKHM1 interaction, which mediates autophagosome-to-lysosome fusion.\",\n      \"method\": \"Co-immunoprecipitation of Rab7A effector interactions in CLN3 KO and CLN3-disease-mutant cells, live-cell imaging, sorting receptor degradation assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP and functional trafficking assays in both KO and disease-mutant cells, two independent pathways (retromer and PLEKHM1) validated\",\n      \"pmids\": [\"32034082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CLN3 and CLN5 function as an endolysosomal complex: CLN5 depletion results in impaired CLN3-Rab7A interactions and downstream effector interactions; CLN3 and CLN5 together regulate endolysosome fusion, autophagy, and retromer function.\",\n      \"method\": \"Co-immunoprecipitation of CLN3-CLN5 complex, Rab7A effector interaction assays after CLN5 depletion, endolysosomal fusion assays, autophagy flux assays\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP and functional assays in CLN5-depleted and CLN3-depleted cells, single lab\",\n      \"pmids\": [\"34060589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CLN3 is required for phagocytosis of photoreceptor outer segments (POS) by retinal pigment epithelium (RPE); a proportion of CLN3 localizes to RPE microvilli. CLN3-disease iPSC-RPE cells show decreased microvilli density and reduced POS binding and ingestion, rescued by wild-type CLN3 gene supplementation.\",\n      \"method\": \"iPSC-RPE from CLN3-disease patients, POS phagocytosis assay (binding and ingestion), immunofluorescence of RPE microvilli, wild-type CLN3 gene rescue\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — patient-derived iPSC model with quantitative phagocytosis assay and gene rescue, two orthogonal phagocytosis endpoints\",\n      \"pmids\": [\"33547385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CLN3 is required for lysosomal egress of glycerophosphodiesters (GPDs), the end products of glycerophospholipid catabolism. Loss of CLN3 causes massive accumulation of GPDs in brain lysosomes of mice and elevated glycerophosphoinositol in CSF of Batten disease patients. CLN3 deficiency also disrupts glycerophospholipid catabolism.\",\n      \"method\": \"LysoTag mouse for tissue-specific lysosome isolation, untargeted metabolite profiling of brain lysosomes by mass spectrometry, CLN3-deficient cultured cells, CSF metabolite analysis from Batten disease patients\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — novel in vivo lysosome isolation method combined with untargeted metabolomics and cell-based validation; replicated in mouse and patient samples\",\n      \"pmids\": [\"36131016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CLN3 functions as a vesicular trafficking hub between Golgi and lysosome compartments: CLN3 interacts with the cation-independent mannose 6-phosphate receptor (CI-M6PR) and multiple endo-lysosomal trafficking proteins. CLN3 depletion causes mis-trafficking of CI-M6PR, mis-sorting of lysosomal enzymes, and defective autophagic lysosomal reformation. CLN3 overexpression promotes formation of multiple lysosomal tubules in a CI-M6PR– and autophagy-dependent manner.\",\n      \"method\": \"Proteomics (CLN3 interactome), co-immunoprecipitation, CI-M6PR trafficking assays, lysosomal enzyme sorting assays, lysosomal tubule formation assays in CLN3 KO and overexpressing cells\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — proteomic interactome plus multiple orthogonal functional assays (M6PR trafficking, enzyme sorting, lysosomal tubule formation) in both loss- and gain-of-function contexts\",\n      \"pmids\": [\"37400440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CLN3 physically interacts with nonmuscle myosin-IIB; loss of CLN3 in Cln3-/- cells causes myosin-IIB distribution abnormalities and a cell migration defect that mimics myosin-II inhibition by blebbistatin.\",\n      \"method\": \"Co-immunoprecipitation of CLN3 and myosin-IIB, scratch assay and transwell migration assay in Cln3-/- cells, blebbistatin inhibition comparison, immunofluorescence of myosin-IIB\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — co-IP interaction plus two independent migration assays with pharmacological mimic, single lab\",\n      \"pmids\": [\"20850431\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CLN3 (battenin) is a multi-pass lysosomal/endosomal transmembrane protein with five transmembrane domains that is N-glycosylated, prenylated (farnesylated at C435), and trafficked from the ER through the trans-Golgi network to lysosomes via AP-1– and AP-3–dependent dileucine and M(X)9G sorting motifs; its primary established function is as a lysosomal egress transporter for glycerophosphodiesters (GPDs) and a vesicular trafficking hub that connects Golgi-to-lysosome transport via interactions with CI-M6PR, regulates late endosomal positioning and dynamics by modulating active Rab7A–effector (retromer, RILP, PLEKHM1) interactions in complex with CLN5, and facilitates trans-Golgi network-to-plasma membrane transport of microdomain-associated proteins including caveolin-1; loss of CLN3 globally disrupts lysosomal enzyme delivery, lipid homeostasis (including BMP synthesis and glycosphingolipid metabolism), endocytic recycling, autophagic lysosomal reformation, photoreceptor outer segment phagocytosis by RPE, and intracellular Ca2+ homeostasis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CLN3 (battenin) is a multi-pass, N-glycosylated lysosomal/endosomal membrane protein whose loss causes juvenile neuronal ceroid lipofuscinosis (Batten disease), established by the identification of a recurrent ~1 kb genomic deletion in patients [#0]. Topologically it spans the membrane five times with a luminal N-terminus and a cytosolic C-terminus [#10], and it is delivered to lysosomes through the trans-Golgi network and the plasma membrane using a dileucine motif and a novel M(X)9G motif that engage the AP-1 and AP-3 adaptor complexes for sequential sorting [#4, #12, #14], a process further dependent on C-terminal farnesylation at cysteine 435 [#16]; the common 461-677del mutant fails this trafficking and is retained in the ER [#3]. At the late endosome/lysosome, CLN3 acts as a vesicular trafficking hub: it binds active GTP-bound Rab7A and RILP and engages microtubule motors to govern endosome positioning [#20], and it controls Rab7A–effector interactions with retromer and PLEKHM1 to drive endosome-to-TGN return of sorting receptors (CI-M6PR, sortilin) and autophagosome–lysosome fusion [#24], functioning in this capacity together with CLN5 as an endolysosomal complex [#25]. Through its interaction with CI-M6PR, CLN3 coordinates Golgi-to-lysosome enzyme delivery and autophagic lysosomal reformation [#28]. A distinct, biochemically defined transport function is the lysosomal egress of glycerophosphodiesters, the end products of glycerophospholipid catabolism, which accumulate in CLN3-deficient brain lysosomes and patient CSF [#27]. Consistent with these roles, CLN3 loss broadly disrupts lysosomal enzyme content and lipid homeostasis, including BMP synthesis and glycosphingolipid metabolism [#17, #23], TGN-to-plasma-membrane transport of microdomain proteins such as caveolin-1 [#21], photoreceptor outer segment phagocytosis by retinal pigment epithelium [#26], and intracellular Ca2+ handling [#22]. Additional reported interactions with cytoskeletal and membrane proteins—fodrin/Na+/K+-ATPase, nonmuscle myosin-IIB, and Hook1—link CLN3 to endocytosis, cell migration, and membrane microdomain organization [#15, #18, #29].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established the genetic basis of Batten disease by identifying CLN3 as a novel gene disrupted by a recurrent genomic deletion, defining the molecular target.\",\n      \"evidence\": \"Exon amplification and genomic deletion/mutation mapping in patient cohorts\",\n      \"pmids\": [\"7553855\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Gene identification gave no protein function\", \"No subcellular localization or biochemical activity defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Resolved where CLN3 acts by confirming it as a lysosomal membrane glycoprotein and showing the common deletion mutant is ER-retained while a missense mutant traffics normally, linking trafficking failure to disease.\",\n      \"evidence\": \"Immunoelectron microscopy, pulse-chase, and mutant comparison in BHK cells and primary neurons; monensin/tunicamycin trafficking studies\",\n      \"pmids\": [\"10332042\", \"9384607\", \"10191113\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular function at the lysosome not established\", \"Sorting machinery not yet identified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined CLN3 membrane topology (five TM domains, luminal N-terminus, cytosolic C-terminus), providing the structural framework for assigning sorting and interaction surfaces.\",\n      \"evidence\": \"In vitro translation with canine microsomes plus glycosylation-site and Flag-tag mutagenesis\",\n      \"pmids\": [\"12706816\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure\", \"Functional residues within TM domains not mapped\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified the dileucine and M(X)9G sorting signals and showed sequential AP-1/AP-3 adaptor-dependent lysosomal delivery, explaining how CLN3 reaches its compartment.\",\n      \"evidence\": \"Targeting-motif mutagenesis, reporter chimeras, in vitro adaptor binding, and AP-1/AP-3-deficient fibroblasts\",\n      \"pmids\": [\"14699076\", \"15469932\", \"15598649\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Conflicting reports on direct adaptor binding via reporter chimeras\", \"Endosomal targeting independent of these motifs not fully explained\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed CLN3 is farnesylated at C435 and that this lipid modification is required for efficient endosomal/lysosomal sorting, adding a post-translational layer to trafficking control.\",\n      \"evidence\": \"Mevalonate metabolic labeling, farnesyltransferase inhibition, and C435 mutagenesis in COS7 and neuronal cells\",\n      \"pmids\": [\"17286803\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic link between prenylation and sorting machinery unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Connected CLN3 to late-endosome dynamics by demonstrating interaction with active Rab7, RILP, and microtubule motors, with a disease mutant causing perinuclear organelle clustering.\",\n      \"evidence\": \"Co-IP, GTP-Rab7 pulldown, and mutant overexpression imaging in HeLa cells\",\n      \"pmids\": [\"22261744\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect Rab7 binding not distinguished\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated through unbiased lysosomal proteomics that CLN3 loss broadly depletes soluble lysosomal enzymes and disrupts lipid and endosomal recycling, establishing global endolysosomal dysfunction.\",\n      \"evidence\": \"SILAC lysosome purification with mass spectrometry, enzyme activity assays, and lipid probes in CLN3 knock-in mouse cells\",\n      \"pmids\": [\"31040178\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not pinpoint the primary biochemical defect upstream of enzyme loss\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Provided the mechanistic basis for enzyme mis-sorting by showing CLN3 regulates Rab7A interactions with retromer and PLEKHM1, controlling sorting-receptor recycling and autophagosome-lysosome fusion.\",\n      \"evidence\": \"Reciprocal co-IP and functional trafficking assays in CLN3 KO and disease-mutant cells\",\n      \"pmids\": [\"32034082\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mode of CLN3 action on Rab7A effectors unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placed CLN3 in a CLN3-CLN5 endolysosomal complex, showing CLN5 is needed for CLN3-Rab7A function and integrating two NCL genes into a shared trafficking pathway.\",\n      \"evidence\": \"Co-IP of the complex, Rab7A effector and autophagy/fusion assays after CLN5 depletion\",\n      \"pmids\": [\"34060589\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry and direct contacts of the complex undefined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined a concrete transport activity by identifying CLN3 as the lysosomal egress route for glycerophosphodiesters, with accumulation in mouse brain lysosomes and patient CSF.\",\n      \"evidence\": \"LysoTag in vivo lysosome isolation, untargeted metabolomics, and cell-based validation plus patient CSF analysis\",\n      \"pmids\": [\"36131016\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct demonstration of CLN3 as the transporter vs facilitator not fully resolved\", \"Relationship between GPD egress and trafficking-hub roles unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Consolidated the trafficking-hub model by showing CLN3 binds CI-M6PR to coordinate Golgi-lysosome enzyme delivery and autophagic lysosomal reformation, with overexpression driving lysosomal tubulation.\",\n      \"evidence\": \"CLN3 interactome proteomics, co-IP, CI-M6PR and enzyme sorting assays, and lysosomal tubule assays in KO and overexpressing cells\",\n      \"pmids\": [\"37400440\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the GPD transport function and the CI-M6PR hub function mechanistically relate is unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Whether CLN3's glycerophosphodiester transport activity and its Rab7A/CI-M6PR trafficking-hub functions reflect a single unified molecular mechanism or separable activities, and how either causes selective neurodegeneration, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of CLN3 in a transport or complex state\", \"Primary defect underlying neuronal death not established\", \"Link between metabolite accumulation and trafficking phenotypes undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [27]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [24, 28]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005765\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [3, 23, 27]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [12, 16, 20]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [4, 21, 28]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [24, 28]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [22, 24, 28]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [17, 23, 27]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [12, 14]}\n    ],\n    \"complexes\": [\n      \"CLN3-CLN5 endolysosomal complex\"\n    ],\n    \"partners\": [\n      \"RAB7A\",\n      \"RILP\",\n      \"PLEKHM1\",\n      \"CLN5\",\n      \"CI-M6PR (IGF2R)\",\n      \"MYH10\",\n      \"SPTAN1\",\n      \"HOOK1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}